ConductScience.org, home

Paper39375168

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

Grisham R and 20 others. Int J Gynecol Cancer, 2025. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. Papers, record 39375168. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375168

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
PubMed
Journal
Int J Gynecol Cancer
PubMed
Year
2025
PubMed
Publication types
Clinical Trial Protocol, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
6.78, provisional
iCite
Revised in PubMed
2026-06-20
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Grisham RRachel
2Monk BJBradley J
3Van Nieuwenhuysen EEls
4Moore KNKathleen Nadine
5Fabbro MMichel
6O'Malley DMDavid M
7Oaknin AAna
8Thaker PPremal
9Oza AMAmit M
10Colombo NNicoletta
11Gershenson DDavid
12Aghajanian CACarol A
13Choi CHChel Hun
14Lee YCYeh Chen
15Mirza MRMansoor Raza
16Coleman RLRobert L
17Cobb LLauren
18Harter PPhilipp
19Lustgarten SStephanie
20Youssoufian HHagop

Source PubMed

See all 21 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Cystadenocarcinoma, SerousMajor topic
Neoplasm Recurrence, LocalMajor topic
Ovarian NeoplasmsMajor topic
Female
Humans
Clinical Trials, Phase III as Topic
Randomized Controlled Trials as Topic
Multicenter Studies as Topic

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06072781A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42891872Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42891872PubMed
42811335Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.J Hematol Oncol2026https://conductscience.org/library/papers/42811335PubMed
42798981Focal adhesion kinase inhibitor defactinib enhances olaparib-induced suppression of BRCA-proficient breast cancer cell proliferation.Oncol Lett2026https://conductscience.org/library/papers/42798981PubMed
42699673Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship.Gynecol Oncol Rep2026https://conductscience.org/library/papers/42699673PubMed
42579369Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.J Clin Invest2026https://conductscience.org/library/papers/42579369PubMed
41899597An FAK Kinase/Scaffold Mode-Switch in Dormancy and Resistance.Cancers (Basel)2026https://conductscience.org/library/papers/41899597PubMed
41826571Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances.Mol Biomed2026https://conductscience.org/library/papers/41826571PubMed
41796449Disarming cancer resistance: FAK as a therapeutic target.Trends Cancer2026https://conductscience.org/library/papers/41796449PubMed
41751910Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Int J Mol Sci2026https://conductscience.org/library/papers/41751910PubMed
41675738Avutometinib (Avmapki): oral RAF/MEK clamp inhibitor advancing precision therapy in KRAS-mutant low-grade serous ovarian cancer.Ann Med Surg (Lond)2026https://conductscience.org/library/papers/41675738PubMed
41584508Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.EXCLI J2025https://conductscience.org/library/papers/41584508PubMed
41392193Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy.NPJ Precis Oncol2025https://conductscience.org/library/papers/41392193PubMed
41193397Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.Future Oncol2025https://conductscience.org/library/papers/41193397PubMed
41041285Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025).RSC Adv2025https://conductscience.org/library/papers/41041285PubMed
40958869Evaluation of anti-liver cancer activity and anticancer mechanism of one novel small molecule compound (THY-10A62) targeting FAK pathway.Front Oncol2025https://conductscience.org/library/papers/40958869PubMed
40908761Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.Int J Gynaecol Obstet2025https://conductscience.org/library/papers/40908761PubMed
40797342Therapeutic landscape of ovarian cancer: recent advances and emerging therapies.Biomark Res2025https://conductscience.org/library/papers/40797342PubMed
40762779Avutometinib and Defactinib: First Approval.Drugs2025https://conductscience.org/library/papers/40762779PubMed
40644648Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.J Clin Oncol2025https://conductscience.org/library/papers/40644648PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DTL51514PubTator's text mininghttps://conductscience.org/library/genes/51514NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
PTK25747PubTator's text mininghttps://conductscience.org/library/genes/5747NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
DEFACTINIBCHEMBL3137331Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3137331ChEMBL
AVUTOMETINIBCHEMBL3264002Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3264002ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39375168

GET https://conductscience.org/api/papers/v1/39375168/authors?page=2